The medical startup MSInsight wants to translate its efforts into clinical practice. The diagnostic tool it is developing, MSICare, is in the process of CE marking. It will make it possible to identify a biomarker of human cancer which radically guides their treatment. The company projects a demand for 500,000 analyzes per year by 2030. It is structuring itself to be able to respond.
Nadia Daki, published on November 25, 2024
Arnaud Cutivet, CEO of MSInsight (left) and the whole team (right). To prepare for its expansion and be able to market its solution beyond the sole field of clinical research, MSInsight is investing in human resources, with several recruitments to come in the coming months. Credit MSInsight
The adventure is not new. Arnaud Cutivet, director and co-founder of MSInsight, would like to point this out. “A multidisciplinary research team from Saint-Antoine Hospital and Inserm in Paris has been working on MSI cancers for more than twenty years. The latter are a family of cancers which represent 5% of all cancer cases worldwide and which are characterized by an instability at the genome level called MSI. “Demonstrating microsatellite instability is a major clinical issue to guide patient care,” he introduces. These microsatellites are present in more than 30 different types of cancer. “If the presence of microsatellite instability is characterized in a patient’s tumor DNA, it indicates that a patient’s tumor will be sensitive to certain immunotherapies. These treatments are very effective, capable of eradicating certain cancers of…
